Could a Vitamin-Like pill protect the brains of people with down syndrome?
NCT ID NCT07278492
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a supplement called MIB-626 (a form of NMN) in 24 adults with Down syndrome. The goal is to see if it is safe and can raise NAD+ levels, which may help protect against Alzheimer's disease. Participants take the pill or a placebo for 28 days and are monitored for side effects and changes in brain chemistry.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MIB-626 (a form of nicotinamide mononucleotide, or NMN)
What this could lead to
If safe and well-tolerated, this could point toward a way to slow or prevent Alzheimer's disease in people with Down syndrome.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. It may not show any benefit, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWN SYNDROME (DS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••